These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 9603399)

  • 1. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
    Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
    Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
    Miyamoto T; Akashi K; Hayashi S; Gondo H; Murakawa M; Tanimoto K; Harada M; Niho Y
    Bone Marrow Transplant; 1996 Feb; 17(2):185-90. PubMed ID: 8640164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.
    Grimm J; Zeller W; Zander AR
    Bone Marrow Transplant; 1998 Jan; 21(1):29-32. PubMed ID: 9486491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
    Mehta R; Shah G; Adler W; Kittur D
    Clin Transplant; 2004; 18 Suppl 12():67-71. PubMed ID: 15217411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease.
    Kobayashi S; Imamura M; Hashino S; Tanaka J; Asaka M
    Leuk Lymphoma; 1997 Dec; 28(1-2):159-69. PubMed ID: 9498715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias.
    Engelhard D; Nagler A; Singer R; Barak V
    Leuk Lymphoma; 1994 Jan; 12(3-4):273-80. PubMed ID: 8167558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients.
    Schroeder TJ; Helling T; McKenna RM; Rush D; Jeffrey JR; Brewer B; Martin LA; Traylor D; Fisher RA; First MR
    Transplantation; 1992 Jan; 53(1):34-40. PubMed ID: 1733082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
    Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
    Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
    Ferrà C; de Sanjosé S; Gallardo D; Berlanga JJ; Rueda F; Marìn D; de la Banda E; Ancìn I; Peris J; Garcìa J; Grañena A
    Haematologica; 1998 Dec; 83(12):1082-7. PubMed ID: 9949625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease.
    Imoto S; Oomoto Y; Murata K; Das H; Murayama T; Kajimoto K; Sugimoto T; Gomyo H; Nakagawa T; Nishimura R; Koizumi T
    Int J Hematol; 2000 Jul; 72(1):92-7. PubMed ID: 10979216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.
    MacMillan ML; Radloff GA; Kiffmeyer WR; DeFor TE; Weisdorf DJ; Davies SM
    Transplantation; 2003 Dec; 76(12):1758-62. PubMed ID: 14688528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble interleukin 2 receptors in patients after bone marrow transplantation.
    Siegert W; Josimovic-Alasevic O; Schwerdtfeger R; Baurmann H; Schmidt CA; Musch R; Schmid HJ; Hartmann R; Henze G; Huhn D
    Bone Marrow Transplant; 1990 Aug; 6(2):97-101. PubMed ID: 2207458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.